374Water Inc. Form 10-Q Summary
Business Context and Reporting Period
374Water develops and commercializes AirSCWO supercritical water oxidation systems intended to recover resources from waste and support clean-water applications. This unaudited Form 10-Q covers the three and nine months ended September 30, 2022, filed November 1, 2022. The company sold its first AirSCWO system to the Orange County Sanitation District on February 1, 2022. It reported 126,680,895 common shares outstanding as of November 1, 2022.
Financial Highlights
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $922,718, versus $19,000 in 2021 | $2,226,477, versus $33,600 in 2021 |
| Gross profit | $110,332, versus $19,000 | $263,598, versus $33,600 |
| Gross margin | Approximately 12.0%, versus 100.0% | Approximately 11.8%, versus 100.0% |
| Operating loss | $(912,988), versus $(552,387) | $(3,001,583), versus $(2,493,568) |
| Net loss | $(912,826), versus $(551,959) | $(2,999,959), versus $(2,492,817) |
| Net loss per share | $(0.01), versus $(0.01) | $(0.02), versus $(0.03) |
| Cash used in operations | Not separately provided for the quarter | $(2,598,193), versus $(1,053,591) |
Operating expenses increased to $1,023,320 in the third quarter and $3,265,181 for the first nine months. Nine-month research and development expense was $726,602, compensation and related expense was $1,135,979, professional fees were $375,313, and general and administrative expense was $1,027,287.
At September 30, 2022, cash was $2,407,983 and marketable securities, primarily U.S. Treasury securities, had a fair value of $5,994,272. Total current assets were $9,864,788, current liabilities were $1,262,157, and working capital was $8,602,631. The filing reports no debt or non-current liabilities. Total assets were $11,005,304 and stockholders’ equity was $9,743,147. The company had an accumulated deficit of $6,159,975.
Material Changes Versus the Prior Comparable Period
- Revenue increased substantially because the company recognized revenue from its first AirSCWO system; prior-period revenue was primarily from treatability studies, consulting, and advisory services.
- Cost of goods sold was $812,386 in the third quarter and $1,962,879 for the first nine months, reducing gross margin from the prior period’s reported 100%.
- Nine-month operating expenses increased $738,013 year over year, driven by higher research and development, compensation, professional fees, and general and administrative costs.
- Cash used in operations increased by $1,544,602 year over year, while the company invested $5,998,243 in marketable securities and $125,011 in equipment.
- Cash declined from $11,131,175 at December 31, 2021 to $2,407,983 at September 30, 2022, while marketable securities increased to $5,994,272 from none at year-end 2021.
- Accounts payable and accrued expenses increased to $1,043,660 from $62,981 at December 31, 2021, and deferred revenue was $200,109 compared with none at year-end.
- All Series D preferred shares were converted into common stock by January 12, 2022. Common shares outstanding increased from 125,317,746 at December 31, 2021 to 126,680,895 at September 30, 2022.
- Management stated that a previously identified material weakness related to entity-level controls, board oversight, and the absence of an audit committee was remediated as of September 30, 2022 following board and committee appointments.
Guidance, Outlook, Risks, and Unusual Items
- Management believes available cash and marketable securities are sufficient to meet financial obligations for at least the next 12 months. The filing provides no formal revenue, earnings, production, or margin guidance.
- The company remains in an early commercialization phase and has generated substantial losses and negative operating cash flow. Future results depend on development, manufacturing, sales, and commercialization of AirSCWO systems.
- Revenue is concentrated: the majority of third-quarter revenue came from the first AirSCWO system sale. Customer concentration and the limited operating history create execution and scalability risks.
- Risks identified include research and development uncertainty, patent and licensing risks, competition, political and economic conditions, interest-rate fluctuations, pricing pressure, technological change, and changes in law and regulation.
- The company incurred $841,577 of related-party manufacturing expenses through September 30, 2022 and accrued $62,858 in related-party manufacturing expenses at quarter-end.
- The Duke University license requires royalties based on licensed product sales and sublicensing fees, plus reimbursement of ongoing patent expenses. No license-related expense was incurred during the third quarter.
- Outstanding equity-linked instruments included 13,392,000 stock options and 1,250,000 warrants as of September 30, 2022, creating potential future dilution. The filing states that no dilutive shares were included in the loss-per-share calculation.
- The financial statements are unaudited, and management cautions that interim results are not necessarily indicative of full-year or future results.
Investor Verification Checklist
- Verify the timing, collectability, and gross margin economics of AirSCWO system sales, including the $200,109 deferred revenue balance.
- Assess the company’s cash runway using operating cash burn, capital expenditures, marketable securities, and expected manufacturing and commercialization needs.
- Review related-party manufacturing arrangements, pricing, accrued balances, and governance safeguards.
- Evaluate whether the reported remediation of the internal-control material weakness remains effective in subsequent filings.
- Track additional equity issuance, option and warrant exercises, and potential dilution against the 200 million authorized common shares.
- Review Duke license royalty obligations, patent costs, and the company’s ability to maintain its technology rights.